Repatha (Evolocumab) Switching Reports: Real Patient Experiences and Clinical Guidance
What happens when patients switch to or from Repatha (evolocumab)? We review real-world switching experiences, clinical trial data from FOURIER, and practical guidance for transitions between PCSK9 inhibitors and other lipid-lowering therapies.
Read clinical review